The FDA is reviewing the resubmitted NDA for sotagliflozin ... Findings from the phase 3 DESTINY PWS trial (ClinicalTrials.gov Identifier: NCT03440814) showed DCCR significantly improved hyperphagia ...
Results that may be inaccessible to you are currently showing.